Salvage nivolumab plus temozolomide associated with improved survival and clinical benefit in refractory melanoma: a retrospective cohort study
- 1Vanderbilt University School of Medicine, Nashville
- 2Department of Biostatistics, Vanderbilt University Medical Center, Nashville
- 3Department of Heme-Onc, Vanderbilt University Medical Center, Nashville
Abstract
Introduction: Patients with metastatic melanoma who progress on standard of care therapy have limited treatment options. This study evaluates the efficacy of nivolumab combined with temozolomide compared to temozolomide alone in this refractory setting.
Methods: We conducted a retrospective cohort study of 44 patients with metastatic melanoma who progressed on prior immunotherapy and systemic therapies. Patients were chemotherapy-naïve and treated at a single center between 2020-2025. Endpoints included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), and progression-free survival (PFS).
Results: Patients treated with nivolumab/temozolomide had improved CBR by over fourfold compared with temozolomide alone. (OR 4.276, 95% CI:1.198-15.268; p=0.025). Median OS was 11.8 months (95% CI: 6.02, NA) with nivolumab/temozolomide versus 5.49 months (95% CI: 1.91-8.97) with monotherapy. Combination therapy was also associated with a lower hazard of death (HR 0.44; 95% CI: 0.205-0.923; p=0.030) and trended toward a lower hazard of progression (HR; 0.531 CI: 0.280-1.008; p=0.053). Exploratory analysis showed a significant treatment-LDH interaction was identified for OS (p=0. 043). Within the subgroup of patients with a baseline LDH over 2 times the upper limit of normal, combination therapy was associated with a significantly reduced hazard of death (HR: 0.183; 95% CI: 0.049-0.690; p=0.012) and progression (HR: 0.205; 95% CI: 0.060-0.692; p=0.011). Nivolumab/temozolomide had numerically higher ORR (36% vs. 10.5%, p=0.053). Combination therapy demonstrated a significantly higher CBR among patients with BRAF mutations compared to monotherapy (90.0% vs. 20.0%, p=0.017).
Conclusions: Nivolumab and temozolomide combination therapy may represent a viable salvage regimen for refractory melanoma.
Related
- Chidamide combined with dinutuximab beta, irinotecan and temozolomide for relapsed or refractory neuroblastoma in children: protocol for a prospective, single-centre, open-label, single-arm, phase II study in China
- Improved efficacy of orelabrutinib plus rituximab, temozolomide and high-dose methotrexate versus rituximab, high-dose methotrexate plus temozolomide in untreated primary CNS lymphoma: A matched analysis
- Selinexor enhances temozolomide efficacy in glioblastoma through modulation of multiple resistance-associated mechanisms
- Laparoscopic para-aortic and pelvic lymphadenectomy before chemoradiotherapy was not associated with improved survival in patients with FIGO stage IIB-IIIC cervical cancer: a single-center retrospective study.
- R0 resection following neoadjuvant PD-1 inhibition with paclitaxel-cisplatin is associated with improved overall survival in locally advanced and recurrent oral squamous cell carcinoma: multicenter retrospective cohort study.
BibTeX
@article{abraham2026salvage,
title = {{Salvage nivolumab plus temozolomide associated with improved survival and clinical benefit in refractory melanoma: a retrospective cohort study}},
author = {Preethy E. Abraham and Kun Bai and Sheau-Chiann Chen and Douglas B. Johnson},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1965090},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1965090/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Salvage nivolumab plus temozolomide associated with improved survival and clinical benefit in refractory melanoma: a retrospective cohort study
AU - Preethy E. Abraham
AU - Kun Bai
AU - Sheau-Chiann Chen
AU - Douglas B. Johnson
PY - 2026
DA - 2026/10/13
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1965090
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1965090/full
AB - Introduction: Patients with metastatic melanoma who progress on standard of care therapy have limited treatment options. This study evaluates the efficacy of nivolumab combined with temozolomide compared to temozolomide alone in this refractory setting. Methods: We conducted a retrospective cohort study of 44 patients with metastatic melanoma who progressed on prior immunotherapy and systemic therapies. Patients were chemotherapy-naïve and treated at a single center between 2020-2025. Endpoints included objective response rate (ORR), clinical benefit rate (CBR), overall survival (OS), and progression-free survival (PFS). Results: Patients treated with nivolumab/temozolomide had improved CBR by over fourfold compared with temozolomide alone. (OR 4.276, 95% CI:1.198-15.268; p=0.025). Median OS was 11.8 months (95% CI: 6.02, NA) with nivolumab/temozolomide versus 5.49 months (95% CI: 1.91-8.97) with monotherapy. Combination therapy was also associated with a lower hazard of death (HR 0.44; 95% CI: 0.205-0.923; p=0.030) and trended toward a lower hazard of progression (HR; 0.531 CI: 0.280-1.008; p=0.053). Exploratory analysis showed a significant treatment-LDH interaction was identified for OS (p=0. 043). Within the subgroup of patients with a baseline LDH over 2 times the upper limit of normal, combination therapy was associated with a significantly reduced hazard of death (HR: 0.183; 95% CI: 0.049-0.690; p=0.012) and progression (HR: 0.205; 95% CI: 0.060-0.692; p=0.011). Nivolumab/temozolomide had numerically higher ORR (36% vs. 10.5%, p=0.053). Combination therapy demonstrated a significantly higher CBR among patients with BRAF mutations compared to monotherapy (90.0% vs. 20.0%, p=0.017). Conclusions: Nivolumab and temozolomide combination therapy may represent a viable salvage regimen for refractory melanoma.
SN - 2234-943X
ER -